The creation of therapeutic monoclonal antibodies has increased recently. mAbs have grown significantly in relevance,
and these compounds are now more crucial than ever in the global biotechnological drug industry. For the treatment of various
diseases, a lot of biotechnology companies are investing in the manufacture of monoclonal antibodies.